Frank Vinluan writes for MedCity News:
In the landscape of mostly injectable Covid-19 vaccines and therapeutics, Meissa Vaccines stands out with its intranasal approach. The company contends that the more patient-friendly dosing option isn’t its only advantage. Easier and more economical to manufacture and store, global distribution of an intranasal vaccine should be less complicated, according to CEO Martin Moore. Crucially, the way Meissa’s vaccine works could also make it better than injectables at blocking viral transmission.
To read the full article, click here.